| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GPR52 |
| Uniprot No | Q9Y2T5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-361aa |
| 氨基酸序列 | MNESRWTEWRILNMSSGIVNVSERHSCPLGFGHYSVVDVCIFETVVIVLLTFLIIAGNLTVIFVFHCAPLLHHYTTSYFIQTMAYADLFVGVSCLVPTLSLLHYSTGVHESLTCQVFGYIISVLKSVSMACLACISVDRYLAITKPLSYNQLVTPCRLRICIILIWIYSCLIFLPSFFGWGKPGYHGDIFEWCATSWLTSAYFTGFIVCLLYAPAAFVVCFTYFHIFKICRQHTKEINDRRARFPSHEVDSSRETGHSPDRRYAMVLFRITSVFYMLWLPYIIYFLLESSRVLDNPTLSFLTTWLAISNSFCNCVIYSLSNSVFRLGLRRLSETMCTSCMCVKDQEAQEPKPRKRANSCSI |
| 预测分子量 | 41,3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GPR52重组蛋白的3篇代表性文献的简要概括(注：文献为示例，非真实存在)：
1. **文献名称**：*Expression and functional characterization of recombinant human GPR52 in HEK293 cells*
**作者**：Komatsu et al. (2017)
**摘要**：研究通过HEK293细胞成功表达并纯化GPR52重组蛋白，证实其与Gs蛋白偶联，激活cAMP信号通路，为靶向GPR52的药物筛选提供模型。
2. **文献名称**：*Crystal structure of the GPR52 transmembrane domain reveals a unique conformation*
**作者**：Zhang et al. (2020)
**摘要**：利用重组GPR52蛋白解析其跨膜区晶体结构，发现不同于其他GPCR的构象特征，为设计特异性激动剂/拮抗剂奠定结构基础。
3. **文献名称**：*GPR52 recombinant protein-based high-throughput screening identifies novel modulators for psychiatric disorders*
**作者**：Smith et al. (2021)
**摘要**：基于重组GPR52蛋白建立高通量筛选平台，发现多个小分子化合物可调节GPR52活性，潜在用于精神分裂症等疾病治疗。
如需真实文献，建议在PubMed或Google Scholar中检索关键词“GPR52 recombinant protein”或“GPR52 expression”。
GPR52 is a class A G protein-coupled receptor (GPCR) initially identified as an orphan receptor due to the lack of known endogenous ligands at the time of its discovery. It is predominantly expressed in the central nervous system, particularly in regions like the striatum, hippocampus, and cortex, suggesting a potential role in modulating neuropsychiatric functions. GPR52 signals primarily through the Gαs pathway, increasing intracellular cAMP levels upon activation. Recent studies have linked it to dopamine and glutamate signaling pathways, implicating its involvement in neurological and psychiatric disorders such as schizophrenia, Huntington’s disease, and Parkinson’s disease.
Recombinant GPR52 protein refers to the genetically engineered form of the receptor produced in heterologous expression systems (e.g., HEK293 or insect cells) for experimental studies. Its production enables detailed biochemical characterization, ligand screening, and structural analysis, which are critical for drug discovery. Unlike native GPR52. the recombinant form is often tagged with fluorescent or affinity markers (e.g., His-tag, FLAG-tag) to facilitate purification, localization, or interaction studies.
Interest in GPR52 has surged due to its potential as a therapeutic target. Agonists or antagonists of GPR52 could modulate aberrant neural circuits in neuropsychiatric diseases. For instance, preclinical studies suggest that GPR52 antagonists might alleviate positive symptoms of schizophrenia by regulating dopamine hyperactivity. Structural insights from recombinant GPR52. including cryo-EM or X-ray crystallography data, are aiding the design of selective compounds. However, challenges remain, such as understanding its endogenous ligand(s) and downstream signaling crosstalk. Recombinant protein tools are pivotal in addressing these gaps, bridging basic research and translational applications.
×
